Pneumagen
Thomas Engelen has a track record in creating value in Listed and in Private Equity backed investments in Life Sciences and Chemicals including financial and operational turn-around as part of MBO and MBI. Support to PE in Due Diligence in various European countries, Brazil and the USA on targets with Enterprise Value up to US$ 1 Billion. Current engagements include Chair at Innovatrain AG and Stan Chem International Ltd.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Pneumagen
1 followers
Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.